HC Wainwright Reaffirms “Buy” Rating for IceCure Medical (NASDAQ:ICCM)

HC Wainwright reiterated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research note released on Tuesday, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock.

Separately, Alliance Global Partners lifted their target price on IceCure Medical from $1.90 to $2.90 and gave the company a buy rating in a research report on Wednesday, March 20th.

IceCure Medical Price Performance

Shares of IceCure Medical stock opened at $0.74 on Tuesday. The stock has a market cap of $33.73 million, a price-to-earnings ratio of -2.24 and a beta of 0.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.88 and a current ratio of 3.39. The stock has a 50 day moving average price of $0.96 and a 200-day moving average price of $1.15. IceCure Medical has a one year low of $0.52 and a one year high of $1.57.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same quarter in the previous year, the business earned ($0.08) EPS. Equities analysts expect that IceCure Medical will post -0.28 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.